Sanofi ADR

NASDAQ: SNY
$57.63
-$0.63 (-1.1%)
Closing Price on September 20, 2024

SNY Articles

Warren Buffett of Berkshire Hathaway Inc. (NYSE: BRK-A) (NYSE: BRK-B) is often considered the greatest investor in modern times.  Some of us think that his status should be one of “The greatest...
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Some mergers are very straight-forward, and others are just odd.  Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. ...
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite.  We have heard enough names around this diabetes treatment...
We have several shares of biotech stocks on the move, but frankly the news from th American Society of Clinical Oncology, or ASCO, looks a bit muted.  So far these are the winners and losers in the...
Berkshire Hathaway Inc. (NYSE: BRK-B, BRK-A) and Warren Buffett have just released their most recent U.S.-listed equity holdings for the Berkshire Hathaway empire. This cut off date is as of March...
The energy sector saw a lot of activity from short sellers in April, but other stocks saw some action as well. We’ve already covered some of the bigger names here and some of the cult stocks here....
Sony (NYSE: SNE) said it would finally turn around is prospects and make money in the next year. Bumbling CEO Sir Howard Stringer is gone. Sony’s core problems are not. It is still in the TV screen...
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is supposed to be acquired by a larger drug company.  It is one of the biggest public merger rumors out there. At least that is the belief of Wall...
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from...
An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this...
Berkshire Hathaway Inc. (NYSE: BRK-B, BRK-A) and Warren Buffett have just released the latest holdings of U.S.-listed equities as of December 31, 2011.  We have included some accompanying notes on...
Dendreon (NASDAQ: DNDN) soared almost 40% in value, or $3.02 a share, in active trading on Thursday after announcing that fourth-quarter revenue from its Provenge prostate-cancer vaccine would exceed...
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms this Thursday morning.  AstraZeneca PLC (NYSE: AZN) Cut to...